AstraZeneca and Ionis Pharmaceuticals’ polyneuropathy drug has won approval in the European Union (EU), where it will be marketed as Wainzua (eplontersen). The drug has been approved to treat ...

AstraZeneca and Ionis Pharmaceuticals’ polyneuropathy drug has won approval in the European Union (EU), where it will be marketed as Wainzua (eplontersen). The drug has been approved to treat ...

Prothena Corporation focuses on neurodegenerative diseases with a diverse pipeline, including Birtamimab for AL amyloidosis, which is in a phase 3 trial. Despite past trial failures, Birtamimab ...

ATTR-CM is the key to that growth, as in ATTR-PN Vyndaqel’s efficacy data isn’t as strong, and it also has competition from Alnylam’s Onpattro (patisiran) and Ionis’ Tegsedi (inotersen ...